On June 5, 2026 Vcare Pharmatech reported NTRK gene fusions have been identified as oncogenic drivers in adult and pediatric patients with pan-solid tumors. A fusion gene is typically formed by the combination of an NTRK gene containing a kinase domain and its fusion partner gene. To date, more than 229 fusion partner genes have been discovered, giving rise to 358 unique fusion-tumor pairings. Patients harboring such fusions generally have a poor prognosis. For advanced solid tumor patients who do not receive targeted therapy, the median overall survival ranges from 10.2 to 12.7 months, and these patients are also at a higher risk of brain metastasis. Meanwhile, the loss of the extracellular domain in NTRK fusions renders antibody-based therapies ineffective. Currently, treatment primarily relies on small-molecule TRK inhibitors that target the kinase domain.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In terms of tumor type distribution, NTRK fusions are characterized by rare mutations with broad tumor spectrum distribution. On one hand, the incidence of NTRK fusions reaches up to 90% in rare malignancies such as secretory breast carcinoma and infantile fibrosarcoma, and ranges from 5% to 25% in papillary thyroid carcinoma and Spitzoid melanoma. On the other hand, real-world data from approximately 295,000 solid tumor patients worldwide indicate that NTRK fusion-positive cases account for a larger absolute number of patients among common cancer types. Collectively, NTRK fusion-positive patients with non-small cell lung cancer, breast cancer, soft tissue sarcoma and colorectal cancer make up nearly 50% of all affected cases, representing the key population requiring close clinical attention. In addition, the prevalence of NTRK fusions is higher in East Asian populations, with an overall incidence of approximately 0.4% among Chinese patients. It is estimated that more than 15,000 new cases of NTRK fusion-positive solid tumors are diagnosed in China each year.4-5

Breaking News: Domestic Next-Generation Tumor-Agnostic Targeted Drug Eratrectinib Approved

On June 4, the official website of the NMPA announced that Vcare PharmaTech’s Class 1 new drug, Eratrectinib, has been approved for marketing in China. It is indicated for adult and adolescent patients with advanced solid tumors harboring NTRK gene fusions.

Efficacy Breakthrough: Eratrectinib Delivers Comprehensive Clinical Benefits

Eratrectinib is a next-generation TRK inhibitor independently developed by Jiangsu Vcare PharmaTech Co.,Ltd.. In pivotal registration clinical trials for patients with NTRK fusion-positive solid tumors, this pan-tumor anticancer agent has demonstrated outstanding efficacy and safety.

Registration study results showed an ORR of 68.5% and a DCR of 85.2%. Among patients followed up for more than 6 months, the ORR reached 89.7% and the DCR was 100%, with a mOS of 40.7 months.6

In terms of long-term clinical benefits, Eratrectinib also achieved impressive results in PFS and DOR. The 2-year PFS rate stood at 75.7% and the 2-year DOR rate hit 85.5%, fully proving that the drug can deliver sustained disease control and long-term remission for patients.

Furthermore, for patients with baseline brain metastases, the ORR was as high as 87.5%. For patients previously treated with TRK-TKIs, the ORR reached 47.4%, reflecting robust therapeutic efficacy across these patient groups.

New Hope for Patients with NTRK Fusion Resistance

As a next-generation TRK inhibitor independently developed in China, Eratrectinib delivers durable and deep tumor remission, with potent brain penetration and a favorable overall safety profile. Different from the linear structure of first-generation TRK inhibitors, Eratrectinib features a cyclic molecular structure. Structural optimization reduces off-target risks and effectively prevents the emergence of drug-resistant mutations, endowing the agent with the anti-resistance mechanisms characteristic of second-generation TRK inhibitors.

(Press release, Jiangsu Vcare PharmaTech, JUN 5, 2026, View Source [SID1234666468])

On June 5, 2026 Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat challenging and aggressive cancers, reported the presentation of two posters at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois. The presentations feature updated pooled data from the Company’s Phase 1 study and expanded access protocol with DOC1021 (dubodencel) in glioblastoma (GBM), as well as the initiation of a Phase 1/2 study (DOC-RM) evaluating DOC1021 in patients with refractory melanoma.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"ASCO provides an important opportunity to share the continued clinical development of DOC1021 across multiple difficult-to-treat cancers," said Jay Hartenbach, President and Chief Operating Officer of Diakonos Oncology. "The pooled GBM data reinforce our confidence in the program, with strong 12‑month survival in a predominantly MGMT unmethylated population, a subgroup associated with poorer outcomes and limited treatment responsiveness. We’re also pleased to introduce our melanoma program, where DOC1021 may offer a differentiated approach to re-engaging the immune system in patients who progress after anti‑PD‑1 treatments."

ASCO Poster Presentations Key Highlights:

Glioblastoma
Abstract Title: Pooled Analysis of Phase I and Expanded Access Study Cohorts of DOC1021 (dubodencel) in Combination with Chemoradiation for Glioblastoma

Updated results combine patients from the Phase 1 study and expanded access protocol, evaluating DOC1021 together with standard therapy in both newly diagnosed and recurrent GBM.

In newly diagnosed patients, overall survival is 18.5 months (8.7 to 38.4 months), with a 90% 12-month survival rate. In recurrent GBM, survival ranged from 10.2 to 22 months post-second surgery. Survival continues to be monitored.
There were no dose-limiting toxicities, with a similar safety profile between studies.
Immune analyses showed consistent activation of memory T cells, supporting a sustained immune response.
A randomized Phase 2 trial is currently enrolling at over 15 clinical sites to further evaluate DOC1021 plus standard of care versus standard of care alone in newly diagnosed GBM.
"This pooled dataset provides important insights into the clinical outcomes and immune responses observed with DOC1021 in glioblastoma," said Dr. Jay-Jiguang Zhu, MD, PhD, Study Investigator at UTHealth Houston (Department of Neurosurgery). "The findings, including the 12-month survival outcomes observed in a predominantly MGMT-unmethylated patient population, support continued investigation of this approach. The ongoing randomized Phase 2 study builds directly on these results and represents an important next step in further evaluating the safety and efficacy of DOC1021 in newly diagnosed glioblastoma."

Refractory Melanoma
Abstract Title: A Phase I/II Clinical Study of DOC1021 (dubodencel) Dendritic Cell Immunotherapy for Refractory Melanoma: Trial in Progress

The Trial-in-Progress poster describes the rationale and design for DOC-RM, an ongoing multi-center Phase 1/2 study evaluating DOC1021 in patients with unresectable or metastatic melanoma who have progressed after prior therapies, including anti‑PD‑1. The study is supported by Diakonos Oncology and a Product Development Research Grant from CPRIT.

The trial includes an initial safety cohort followed by an expansion phase to evaluate tumor response, where patients will receive two courses of DOC1021 with pegylated interferon, and an optional booster approximately six months later.
Preclinical data showed improved tumor responses in multiple models, including B16F10 melanoma, supporting exploration in PD‑1 refractory disease.
The clinical study is now actively enrolling at leading cancer centers, including City of Hope, the University of Alabama at Birmingham, and Massachusetts General Hospital.
"Patients with unresectable or metastatic melanoma who progress after anti-PD-1 therapy have limited treatment options, highlighting the need for continued investigation of new immunotherapy approaches," said Alexandra (Lexi) Haugh, MD, MPH, Principal Investigator at Massachusetts General Hospital Cancer Center for the DOC-RM study. "DOC1021 utilizes an individualized dendritic cell-based strategy designed to present a broad range of patient-specific tumor antigens, and avoids the need for myeloablative chemotherapy and IL-2. We’re excited to begin and help evaluate the safety and feasibility of this approach for patients with refractory melanoma."

About DOC1021

DOC1021 is a first-in-class, patient-derived double-loaded dendritic cell therapy that combines tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a patient’s own dendritic cells combined with mRNA and proteins prepared from freshly obtained patient tumor specimens.

The unique double-loading approach, a physiologic mimic of viral infection, unlocks a synergistic and exponentially more powerful tumor killing response that permits complete targeting of the total cancer antigen pool. Moreover, the approach does not require any molecular modification or genetic engineering of the patient’s immune cells and does not require preconditioning chemotherapy or high dose IL-2 for administration. DOC1021 is designed for outpatient administration and broad access via community cancer centers.

Diakonos currently has three actively enrolling clinical trials evaluating DOC1021, including a Phase 1 pancreatic cancer study (NCT04157127), a Phase 2 glioblastoma (GBM) study (NCT06805305) and a Phase 1/2 study in refractory melanoma (NCT07288112) supported by the Cancer Prevention and Research Institute of Texas (CPRIT). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DOC1021 for the treatment of pancreatic cancer, GBM, and unresectable or metastatic cutaneous melanoma, reflecting the significant unmet medical need across these indications. Diakonos also received Orphan Drug Designation for the GBM program in January 2024.

(Press release, Diakonos Oncology, JUN 5, 2026, View Source [SID1234666469])

On June 5, 2026 Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, reported a multi-year collaboration with Sanofi to co-develop next-generation biopharma agents, to be backed by a five-year license for K Pro, Owkin’s AI Scientist.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Owkin and Sanofi have collaborated since 2021 through a €90 million strategic partnership focused on target identification in oncology and patient subgrouping. The collaboration was later expanded to include drug positioning for Sanofi’s immunology pipeline. This new collaboration represents the next evolution in the partnership.

During the five-year collaboration, Owkin will lead the end-to-end development of novel AI-driven biopharma agents purpose-built for Sanofi. These AI agents will work like intelligent assistants, autonomously performing complex tasks in drug research and development. They will be deployed through K Pro, with the aim of complementing and reinforcing Sanofi’s existing agentic AI capabilities.

K Pro combines multimodal patient data with specialized biological, agentic AI systems to support each stage of the pharmaceutical value chain, from early discovery through clinical development, while providing competitive intelligence, enabling faster, more informed, and more precise decisions.

"Building on our collaboration with Sanofi, this marks a shift toward truly embedded AI," said Thomas Clozel, CEO and co-founder of Owkin. "Owkin believes that, with K Pro, Sanofi can further harness agentic systems within their own workflows, unlocking the full value of their data to accelerate better decisions across drug development."

"Across Sanofi, we are continually investing in frontier AI solutions with the potential to accelerate and improve decision-making throughout the drug development lifecycle," said Emmanuel Frenehard, Chief Digital Officer at Sanofi. "By implementing purpose-built agentic systems into our workflows, we aim to empower our teams to operate with greater speed, depth, and confidence as we continue to work to deliver transformative outcomes for patients."

K Pro’s development is part of Owkin’s mission to achieve Biological Artificial Superintelligence to unlock new therapeutic discoveries beyond the limits of human cognition alone. Owkin believes this technology will enable the pharmaceutical industry to address, and ultimately automate, some of the most complex challenges in R&D.

(Press release, Sanofi, JUN 5, 2026, View Source [SID1234666470])

On June 5, 2026 Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, reported that management will participate in the Goldman Sachs 47th Annual Global Healthcare Conference 2026. With an initial focus in oncology, Foghorn’s Gene Traffic Control platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Goldman Sachs 47th Annual Global Healthcare Conference 2026

Fireside Chat: Tuesday, June 9, 2026, at 1:20 p.m. EDT
Presenter: Adrian Gottschalk, President and Chief Executive Officer
Registration link: Register here
Management will also participate in one-on-one meetings
A webcast of the fireside chat can be accessed under "Events & Presentations" in the Investors section of the Company’s website here and will be available for 90 days.

(Press release, Foghorn Therapeutics, JUN 5, 2026, View Source [SID1234666471])

On June 5, 2026 Kura Oncology, Inc. (the "Company") (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that on June 1, 2026, the Compensation Committee of the Company’s Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 53,000 shares of common stock to four (4) new employees under the Company’s 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Each stock option has an exercise price equal to $9.04 per share, the closing price of the Company’s common stock on June 1, 2026, and will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the applicable vesting commencement date and the balance of the underlying shares vesting monthly thereafter over 36 months, subject to the new employees’ continued service relationship with the Company through the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2023 Inducement Option Plan, as amended, and the terms and conditions of an applicable stock option agreement covering the grant.

(Press release, Kura Oncology, JUN 5, 2026, View Source [SID1234666473])